Deferasirox: Treatment of iron overload iron chelator

Drugs of the Future

Volumn 29, Issue 4, 2004, Pages 331-335

  McIntyre, J A ^a   Castaner J ^a   Mealy, N E ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CARBON 14; CYTOCHROME P450; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRIC HYDROXIDE; IRON; IRON CHELATING AGENT; ORPHAN DRUG; PLACEBO;

ABDOMINAL PAIN; BETA THALASSEMIA; BIOACCUMULATION; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; EXPERIMENTAL MODEL; HUMAN; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; NAUSEA; NONHUMAN; OUTCOMES RESEARCH; PHARMACODYNAMICS; PHARMACOKINETICS; RASH; REVIEW; SICKLE CELL ANEMIA;

EID: 2642553714     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.04.791758     Document Type: Review

References (27)

1. Lattmann, R., Acklin, P. (Novartis AG). Substd. 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators. EP 0914118, JP 2000507601, US 6465504, US 2003069273, US 6596750, WO 9749395.
2. The Thalassemia Syndromes, D.J.Weatherall and J.B. Clegg (Eds.), 4th Ed., Blackwell Scientific, Oxford, 2001.
3. Cohen, A. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987, 1: 521-44.
4. Pippard, M.J., Weatherall, D.J. Oral iron chelation therapy for thalassaemia: An uncertain scene. Br J Haematol 2000, 111: 2-5.
5. Porter, J.B. Practical management of iron overload. Br J Haematol 2001, 115: 239-52.
6. Nick, H., Acklin, P., Lattmann, R., Buehlmayer, P., Hauffe, S., Schupp, J., Alberti, D. Development of tridentate iron chelators: From desferrithiocin to ICL670. Curr Med Chem 2003, 10: 1065-76.
7. Sephton-Smith, R. Iron excretion in thalassaemia major after administration of chelating agents. BMJ - Br Med J 1962, (5319): 1577-80.
8. Olivieri, N.F., Brittenham, G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89: 739-61.
9. Barman Balfour, J.A., Foster, R.H. Deferiprone: A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases. Drugs 1999, 58: 553-78.
10. Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D., Fleming, K.A. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New Engl J Med 1998, 339: 417-23.
11. Hershko, C., Konijn, A.M., Nick, H.P., Breuer, W., Cabantchik, Z.I., Link, G. ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001, 97: 1115-22.
12. Hershko, C., Konijn, A.M., Nick, H.P., Link, G. ICL670A, a powerful new synthetic oral iron chelator: Evaluation of hypertransfused rats and in cultured iron-loaded rat heart cells. Blood 2000, 96(11, Part 1): Abst 961.
13. Nick, H., Wong, A., Acklin, R, Faller, B., Jin, Y., Lattmann, R., Sergejew, T., Hauffe, S., Thomas, H., Schnebli, H.P. ICL670A: Preclinical profile. Adv Exp Med Biol 2002, 509: 185-203.
14. Sergejew, T., Forgiadni, P., Schnebli, H.P. Chelator-induced iron excretion in iron-overloaded marmosets. Br J Haematol 2000, 110: 985-92.
15. Galanello, R. Iron chelation: New therapies. Semin Hematol 2001, 38(1, Suppl. 1): 73-6.
16. Goudeau, C., Loyevsky, M., Kassim, O.O., Gordeuk, V.R., Nick, H. Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum. Br J Haematol. 2001, 115: 918-23.
17. Rouan, M.C., Marfil, F., Mangoni, P., Sechaud, R., Humbert, H., Maurer, G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B - Biomed Sci Appl 2001, 755:203-13.
18. Porter, J.B., Waldmeier, F., Bruin, G. et al. Pharmacokinetics, metabolism and elimination of the iron chelator drug ICL670 in beta-thalassemia patients. Blood 2003, 102(11, Part 2): Abst 3720.
19. Galanello, R., Piga, A., Alberti, D., Rouan, M.C., Bigler, H., Sechaud, R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 2003, 43: 565-72.
20. Piga, A., Galanello, R., Dessi, C., Sedaro, M., Loehrer, F., Séchaud, R., Bigler, H., Origa, R., Tartaglia, N., Alberti, D. A novel oral iron chelator (ICL670A): Results of a phase I single-dose safety study. 41st Annu Meet Am Soc Hematol (Dec 3-7, New Orleans) 1999, Abst 3304.
21. Nisbet-Brown, E., Olivieri, N.F., Giardina, P.J. et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003, 361: 1597-602.
22. Nisbet-Brown, E., Olivieri, N.F., Giardina, P.J., Grady, R.W., Sizer, K., Sechaud, R., Rosenkranz, G., Alberti, D., Nathan, D.G. ICl670A, a tridentate orally-active iron chelator, provides net negative iron balance and increased serum iron binding capacity, in iron-overloaded patients with thalassemia. Blood 2001, 98(11, Part 1): Abst 3111.
23. Giardina, P., Olivieri, N.F., Grady, R.W., Sizer, K.C., Sechaud, R., Krebs-Brown, A.J., Alberti, D., Nathan, D.G. ICL670, a tridentate orally-active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron-overloaded patients with thalassemia. 7th Congr Eur Hematol Assoc (June 6-9, Florence) 2002, Abst 0236.
24. Piga, A., Galanello, R., Cappellini, M.D., Forni, G.-L., Lupo, G., Ford, J.M., Sechaud, R., Mueller, C., Opitz, H., Alberti, D. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood 2003, 102(11, Part 1): Abst 412.
25. Piga, A., Galanello, R., Cappellini, M.D., Forni, G.-L., Opitz, H., Ford, J.M., Sechaud, R., Mueller, C., Donato, G., Alberti, D. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood 2002, 100(11, Part 1): Abst 5.
26. Cappellini, M.D., Galanello, R., Piga, A. et al. Update on the effects of ICL670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Congr Eur Hematol Assoc (June 6-9, Florence) 2002, Abst 0610.
27. Cappellini, M.D., Galanello, R., Piga, A., Forni, G.L., Opitz, H., Ford, J.M., Sechaud, R., Mueller, C., Alberti, D. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congr Eur Hematol Assoc (June 12-15, Lyon) 2003, Abst 0909.